Alcohol and drug use among Durham Region Students infographic

| August 25, 2015

article image
Substance use before the age of 25 can lead to brain damage and long term problems because the brain is not fully developed until people are in their mid-twenties. Youth are at a high risk when drinking alcohol as they are more likely to drink large amounts at one time. Teens are watching what you do as a parent and your behaviour affects them. Think about your own opinions and substance use, and what messages they are sending to your teen.

Spotlight

Burrard Pharmaceuticals

Burrard Pharmaceuticals is an international leading biopharmaceutical company. We have access to modern state-of-the-art pharmaceutical facilities. The operational efficiency of our facility results in diverse production options, reduced lifecycle costs and compliance to all pharma GMP regulations. We have extensive expert resources combining unique processes and full technology integration. Since our founding in 2005, we are at the forefront of drug manufacturing and technology transfer.

OTHER ARTICLES

Roche Prepares to Launch COVID-19 Antibody Test System

Article | April 17, 2020

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease. This morning, Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2, the virus that causes COVID-19. Roche is eying May for the launch of the test in Europe and is in talks with the U.S Food and Drug Administration for emergency approval of the system. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms, the company said. Roche noted that as more information becomes available about immunity levels to COVID-19, society can return to a sense of normal much more quickly. Roche’s test will join a number of other antibody tests that have recently come on the market. Earlier this month the U.S. Food and Drug Administration approved the first blood test for COVID-19 antibodies.

Read More

Pricing of drugs – at what cost?

Article | February 27, 2020

We go into a doctor’s office and leave with a diagnosis and a prescription. Next we stop by the pharmacy. In Germany, if your insurance is not private, you mostly don’t even know the price of your drug because it’s paid for directly by your insurance. You only notice the 5-10 Euros copay. But how is a drug priced in Germany? And (how) does data play a role in helping pharma secure an attractive price point? Let’s fast forward directly to the launch of a new drug. At the time of launch, the pharmaceutical company has to present patient level evidence of the drug’s added value compared to existing comparative therapies. In the first year, however, the drug’s price can be defined freely by the company.

Read More

Comparing HydroxyChloroquine Trials

Article | April 1, 2020

One minor side effect of the pandemic is that perhaps more people will learn about what drug research and clinical trials can really be like. Today’s example: we have a clinical trial of hydroxychloroquine from Wuhan that has just published on a preprint server. What’s good is that this one is blinded, randomized, and controlled (like the earlier hydroxychloroquine which one I blogged about here from Zhejiang University, so we can actually talk about it rather than just spend all our time wondering what the heck is going on.

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | April 1, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Spotlight

Burrard Pharmaceuticals

Burrard Pharmaceuticals is an international leading biopharmaceutical company. We have access to modern state-of-the-art pharmaceutical facilities. The operational efficiency of our facility results in diverse production options, reduced lifecycle costs and compliance to all pharma GMP regulations. We have extensive expert resources combining unique processes and full technology integration. Since our founding in 2005, we are at the forefront of drug manufacturing and technology transfer.

Events